StockNews.AI
MDGL
StockNews.AI
188 days

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

1. Madrigal will release Q4 and full-year 2024 results on Feb 26, 2025. 2. Management will host a webcast to discuss financial and operating results. 3. Rezdiffra is designed to treat high unmet medical need in liver disease.

3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings reports may not show significant surprises; similar past reports had stable impact.

How important is it?

Earnings results could influence investor perception, but lack major catalysts.

Why Short Term?

Immediate market reactions typically follow earnings announcements; longer-term effects will depend on results.

Related Companies

MDGL
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two hours after the live webcast. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com. Investor ContactTina Ventura, IR@madrigalpharma.com Media ContactChristopher Frates, media@madrigalpharma.com

Related News